Metraipolis › archive › dc_cbd800bda4cb
Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5-Year Real-Life Experience With Dupilumab — Europe PMC PMID:41531105
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41531105
- DOI
- 10.1111/ijd.70260
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T20:46:45.333Z
- SHA-256 of the archived text
544c55cf025d288fe9ff462989d90b4d9d6028c71783fb2dae5b470992f7fb64- Stable URL of this page
https://metraipolis.com/documento/dc_cbd800bda4cb
How to cite
Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5-Year Real-Life Experience With Dupilumab — Europe PMC PMID:41531105 — Europe PMC (en), https://europepmc.org/article/MED/41531105 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cbd800bda4cb (Metraipolis archive dc_cbd800bda4cb, sha256 544c55cf025d288fe9ff462989d90b4d9d6028c71783fb2dae5b470992f7fb64)
BibTeX
@misc{dccbd800bda4cb,
title = {Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5-Year Real-Life Experience With Dupilumab — Europe PMC PMID:41531105},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41531105},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cbd800bda4cb; sha256 544c55cf025d288fe9ff462989d90b4d9d6028c71783fb2dae5b470992f7fb64},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41531105. Agents can read the archived copy with the MCP tool read_document.